Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 12.56 at 10:45 am ET, low 12.05 at 3:30 pm ET.
the bull case· 2
+9.12%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '264
of the funds on file reporting a position in GLUE
n-portas of Jun 30 '26the bear case· 4
8 of 8
recent reports where the move came in under the options-implied range
earnings historyimplied vs realized8 of 24
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2626
managers whose positions together make up four fifths of the reported value
13fJun 30 '260.48%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Of the 6 companies Monte Rosa Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2836, Biological Products, (No Diagnostic Substances), from each company's own filings. Largest first.
193 managers report a position worth $2.3B between them, and 26 of them hold 80% of it.
tall tick = annual report · 1 on record
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
GLUE (Monte Rosa Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.